Roivant Sciences Ltd. (ROIVW)
NASDAQ: ROIVW
· Real-Time Price · USD
2.75
0.12 (4.56%)
At close: Jan 16, 2025, 10:00 PM
Company Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
The company was founded in 2014 and is based in London, the United Kingdom.
Roivant Sciences Ltd.

Country | GB |
IPO Date | Sep 27, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 620 |
CEO | n/a |
Contact Details
Address: 11-12 St. James’s Square London, GB | |
Website | http://roivant.com |
Stock Details
Ticker Symbol | ROIVW |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001635088 |
CUSIP Number | G76279119 |
ISIN Number | n/a |
Employer ID | 98-1173944 |
SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 05, 2025 | 4 | Filing |
Sep 03, 2025 | 8-K | Current Report |
Sep 02, 2025 | 4 | Filing |
Aug 22, 2025 | 4 | Filing |
Aug 22, 2025 | 4 | Filing |
Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Aug 11, 2025 | 10-Q | Quarterly Report |
Aug 11, 2025 | 8-K | Current Report |
Aug 07, 2025 | SCHEDULE 13G | Filing |